Home testing kits, coordinated outreach improve CRC screening rates

Harnessing big data and AI to combat colorectal cancer

In the rapidly evolving field of oncology, the integration of big data and artificial intelligence is revolutionizing our approach to cancer research and treatment. The future of precision oncology requires integrating computational approaches with clinical practice.

May 23, 2025

Vol.51 No.20

By Enrique Velazquez Villarreal

Drugs & Targets

Cardiac CT scanner receives FDA clearance

Arineta, a provider of cardiovascular imaging solutions, announced that its SpotLight Duo cardiac CT scanner has received 510(k) clearance from FDA for low-dose lung cancer screening. This clearance allows providers to use a single ultra-fast CT platform for both cardiac and lung imaging and diagnostics, delivering more complete care to high-risk patients.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Study assesses advancing racial equity in cancer care through multimodal AI

Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the publication of a validation study in the JCO Clinical Cancer Informatics on Artera’s MMAI model.

May 16, 2025

Vol.51 No.19

Clinical Roundup

Quest Diagnostics report shows oncologists see more advanced cancers, say current tests not catching recurrence early enough

According to a recent report, “The Cancer Paradox: Oncologists’ Perspectives on Barriers to Advanced Cancer Care and Recurrence Monitoring,” oncologists believe they are seeing more and more patients with advanced cancers, and that screening barriers are the leading reason why. They worry that current tests may not catch cancer recurrence early enough.

May 16, 2025

Vol.51 No.19

Clinical Roundup

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a phase III clinical trial by researchers at City of Hope.

May 02, 2025

Vol.51 No.17

Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

April 25, 2025

Vol.51 No.16

By Richard M. Goldberg